VKTX Stock Recent News

Viking Therapeutics Inc (NASDAQ: VKTX) is up nearly 20% on Tuesday after reporting encouraging early-stage data for its experimental weight-loss oral drug. Is Viking Therapeutics' oral weight-loss drug effective?

The Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.

Viking Therapeutics said on Tuesday its experimental tablet helped reduce weight in patients in an early-stage trial and was shown to be safe and effective in the study.

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the way.

Viking Therapeutics stock has been soaring this year due to optimism about its weight loss drug candidate. The stock is a risky buy, however, as the company isn't profitable or generating any consistent revenue.

Three very different potential scenarios for Viking Therapeutics' future seem possible. Only one of these potential scenarios is negative for Viking's shareholders.

Eli Lilly's weight loss drugs are helping it conquer what may become a $100 billion market. Viking Therapeutics recently announced promising trial data for its weight loss candidate -- which works in the same way as the Lilly drugs.

The biotech is getting a lot of attention for one of its pipeline drugs. VK2735 looks like it has a solid chance at becoming a blockbuster obesity treatment.

A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.

Viking Therapeutics is going to market with its first medicine for obesity. If that drug and its peers are widely adopted, many things may change.